The findings published in the journal -- Science Advances today - revealed exceptionally promising results for the Chikungunya vaccine candidate which has been engineered using a synthetic protein scaffold that could revolutionise the way vaccines are designed produced and stored. Researchers from the University of Bristol and the French National Centre for Scientific Research (CNRS) in Grenoble France teamed up with computer technology giant Oracle to find a way to make vaccines that are thermostable (able to withstand warm temperatures) can be designed quickly and are easily produced. We were working with a protein that forms a multimeric particle resembling